Droplet Digital PCR as a Molecular Tool for the Detection of the EGFR T790M Mutation in NSCLC Patients with the EGFR Activating Mutations

1 Garinet S, Laurent-Puig P, Blons H, Oudart J-B. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018; 7(6):144. GarinetS Laurent-PuigP BlonsH OudartJ-B Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018 7 6 144 Search in Google Scholar

2 Rodak O, Peris-Diaz MD, Olbromski M, Podhorska-Okolow M, Dziegiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers. 2021; 13(18):4705. RodakO Peris-DiazMD OlbromskiM Podhorska-OkolowM DziegielP Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy Cancers 2021 13 18 4705 Search in Google Scholar

3 Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18:1454–66. WuYL ChengY ZhouX LeeKH NakagawaK NihoS Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Lancet Oncol 2017 18 1454 66 Search in Google Scholar

4 Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2):113–25. SoriaJ-C OheY VansteenkisteJ ReungwetwattanaT ChewaskulyongB LeeKH Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med 2018 378 2 113 25 Search in Google Scholar

5 Salihefendić L, Pećar D, Konjhodžić R. Validation of CRC and NSCLC somatic mutations detected with NGS using ddPCR. Genetics & Applications. 2019; 3(1):71–6. SalihefendićL PećarD KonjhodžićR Validation of CRC and NSCLC somatic mutations detected with NGS using ddPCR Genetics & Applications 2019 3 1 71 6 Search in Google Scholar

6 Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013; 31:1070–80. OhashiK MaruvkaYE MichorF PaoW Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease J Clin Oncol 2013 31 1070 80 Search in Google Scholar

7 Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240–7. YuHA ArcilaME RekhtmanN SimaCS ZakowskiMF PaoW Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 2013 19 8 2240 7 Search in Google Scholar

8 Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PloS Med. 2005; 2(3):73. PaoW MillerVA PolitiKA RielyGJ SomwarR ZakowskiMF Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PloS Med 2005 2 3 73 Search in Google Scholar

9 Cunha Santos G, Shepherd FA, Tsao MS. EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011; 6(1):49–69. Cunha SantosG ShepherdFA TsaoMS EGFR Mutations and Lung Cancer Annual Review of Pathology: Mechanisms of Disease 2011 6 1 49 69 Search in Google Scholar

10 Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019; 79(4):689–98. MurtuzaA BulbulA ShenJP KeshavarzianP WoodwardBD Lopez-DiazFJ Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer Cancer Res 2019 79 4 689 98 Search in Google Scholar

11 Rodriguez J, Avila J, Rolfo C, Ruiz-Patino A, Russo A, Ricaurte L et al. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther. 2021; 9(1):89–110. RodriguezJ AvilaJ RolfoC Ruiz-PatinoA RussoA RicaurteL When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review Oncol Ther 2021 9 1 89 110 Search in Google Scholar

12 Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10(8):472–484. CrowleyE Di NicolantonioF LoupakisF BardelliA Liquid biopsy: monitoring cancer-genetics in the blood Nat Rev Clin Oncol 2013 10 8 472 484 Search in Google Scholar

13 Droplet DigitalTM PCR Applications Guide (lab handbook). Hercules, California: Bio-Rad Laboratories Inc ; 2017. Droplet DigitalTM PCR Applications Guide (lab handbook) Hercules, California Bio-Rad Laboratories Inc 2017 Search in Google Scholar

14 QIAamp^® Circulating Nucleic Acid Handbook. Hilden, Germany: Qiagen, 2019. QIAamp^® Circulating Nucleic Acid Handbook Hilden, Germany Qiagen 2019 Search in Google Scholar

15 QIAvac 24 Plus Handbook (lab handbook). Hilden, Germany: Qiagen, 2010. QIAvac 24 Plus Handbook (lab handbook) Hilden, Germany Qiagen 2010 Search in Google Scholar

16 Qubit^® dsDNA HS Assay Kits (lab handbook). Carlsbad, California: Life Technologies, 2015. Qubit^® dsDNA HS Assay Kits (lab handbook) Carlsbad, California Life Technologies 2015 Search in Google Scholar

17 ddPCRTM EGFR T790M Screening Kit (lab handbook). Hercules, California: Bio-Rad Laboratories Inc ; 2016. ddPCRTM EGFR T790M Screening Kit (lab handbook) Hercules, California Bio-Rad Laboratories Inc 2016 Search in Google Scholar

18 Kim Y, Shin S, Lee KA. Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy. Cancer Cell Int. 2021; 21(50). KimY ShinS LeeKA Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy Cancer Cell Int 2021 21 50 Search in Google Scholar

19 Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B, Lynch D, de Souza P, Roberts T. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thorac Cancer. 2019; 10(10):1879–1884. DingPN BeckerT BrayV ChuaW MaY XuB LynchD de SouzaP RobertsT Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib Thorac Cancer 2019 10 10 1879 1884 Search in Google Scholar

20 Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N Engl J Med. 2005; 352(8): 786–92. KobayashiS BoggonTJ DayaramT JannePA KocherO MeyersonM EGFR mutation and resistance of non-small-cell lung cancer to geftinib N Engl J Med 2005 352 8 786 92 Search in Google Scholar

21 Wang W, Song Z, Zhang Y. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Medicine. 2016; 6(1): 154–162. WangW SongZ ZhangY A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance Cancer Medicine 2016 6 1 154 162 Search in Google Scholar

22 Yoon HJ, Lee HY, Lee KS, Choi, Y-L, Ahn M-J, Park K et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology. 2012; 265(3): 939–948. YoonHJ LeeHY LeeKS ChoiY-L AhnM-J ParkK Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications Radiology 2012 265 3 939 948 Search in Google Scholar

23 Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2014; 86(2):170–3. ChouaidC DujonC DoP MonnetI MadroszykA Le CaerH Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01) Lung Cancer 2014 86 2 170 3 Search in Google Scholar

24 Silveira C, Sousa AC, Janeiro A, Malveiro S, Teixeira E, Brysch E et al. Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR. Transl Lung Cancer Res, 2021; 10(3): 1200–1208. SilveiraC SousaAC JaneiroA MalveiroS TeixeiraE BryschE Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR Transl Lung Cancer Res 2021 10 3 1200 1208 Search in Google Scholar

25 Jung A, Kirchner T. Liquid Biopsy in Tumor Genetic Diagnosis. Deutsches Arzteblatt international, 2018; 115(10): 169–174. JungA KirchnerT Liquid Biopsy in Tumor Genetic Diagnosis Deutsches Arzteblatt international 2018 115 10 169 174 Search in Google Scholar

26 Chan KCA, Jiang PY, Zheng YWL, Liao GJW, Sun H, Wong J et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem, 2013; 59(1): 211–24. ChanKCA JiangPY ZhengYWL LiaoGJW SunH WongJ Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing Clin Chem 2013 59 1 211 24 Search in Google Scholar

27 Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Scientific Reports, 2016; 6,20913. ZhengD YeX ZhangMZ SunY WangJY NiJ Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance Scientific Reports 2016 6 20913 Search in Google Scholar